PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Gastric cancer (GC) remains a leading cause of cancer mortality globally.
• Immune checkpoint inhibitors, particularly PD-L1/PD-1 inhibitors, represent a significant advancement in GC treatment, enhancing anti-tumor immunity and patient prognosis.

Purpose of the Study:

• To review the endogenous and exogenous regulatory mechanisms of Programmed Death-Ligand 1 (PD-L1) in gastric cancer.
• To explore the biological functions of PD-L1 and its role in current clinical trials of PD-L1/PD-1 inhibitors for GC.
• To discuss how understanding PD-L1 regulation can improve immunotherapy efficacy and patient outcomes.

Main Methods:

• Literature review of regulatory mechanisms of PD-L1.
• Analysis of biological functions of PD-L1 in GC.
• Summary of current clinical trials involving PD-L1/PD-1 inhibitors in GC.
• Examination of PD-L1's role in malignant phenotypes and treatment strategies.

Main Results:

• PD-L1 plays a crucial role in mediating anti-tumor immune responses in GC.
• Various endogenous and exogenous factors regulate PD-L1 expression in GC.
• PD-L1/PD-1 inhibitors have demonstrated significant anti-tumor efficacy in clinical settings.
• Identifying biomarkers for immunotherapy response is essential for personalized treatment.

Conclusions:

• Further elucidation of PD-L1 regulatory mechanisms is critical for optimizing GC immunotherapy.
• Personalized immunotherapy strategies, guided by biomarkers and molecular characteristics, can maximize clinical benefits and improve patient prognosis.